LEO 22811 - A Phase 1, Double-Blind, Placebo-controlled, Single and Multiple Oral Dose Study in Healthy Subjects

Authors LEO Pharma -More
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2009
Links ClinicalTrials.gov
The purpose of this first-in-man trial is to determine the safety and tolerability of ascending single and multiple doses of LEO 22811 in healthy male subjects as well as to determine the safety and tolerability of single oral doses of LEO 22811 in healthy female subjects. The trial will be performed in two parts. In Part 1, single doses of LEO 22811 will be administered to healthy male and female subjects. In Part 2, multiple doses of LEO 22811 will be administered to healthy male subjects.
Epistemonikos ID: beca69c5c9b071cf41376f5506b8bf5d7c5db44d
First added on: May 05, 2024